Citation Impact
Citing Papers
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
1997 Standout
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
1989 Standout
Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres
2010 Standout
Etoposide: four decades of development of a topoisomerase II inhibitor
1998 Standout
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
1991 Standout
A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days
1993
Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients
1989
Clinical Factors and Prognosis in Non–Small Cell Lung Cancer
1999
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Metabolism and reactions of quinoid anticancer agents
1987
A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
1990 Standout
Head and neck cancer
2008 Standout
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
1995
Pharmacodynamics in cancer therapy.
1990
Molecular mechanisms of resistance and toxicity associated with platinating agents
2006 Standout
Definition and classification of cancer cachexia: an international consensus
2011 Standout
Anthrazykline in der Krebstherapie
1997 Standout
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Cancer-associated cachexia
2018 Standout
Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin
1987
Polymer conjugates as anticancer nanomedicines
2006 Standout
Carboplatin
1989
Potential Role of Oral Anthracyclines in Older Patients with Cancer
1994
Prognostic Factors in Superficial Bladder Tumors. A Study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group
1983
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
2006 Standout
Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
1991
Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer.
1987
Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
1994
Iproplatin and carboplatin induced toxicities: Overview of phase II clinical trial conducted by the EORTC early clinical trials cooperative group (ECTG)
1988
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
1992 Standout
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial
2011
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
1990 Standout
Management of malignant pleural effusions
2001 Standout
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.
1989
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Clinical Pharmacokinetics of Carboplatin
1988
A Risk-Benefit Assessment of Anthracycline Antibiotics in Antineoplastic Therapy
1996
Prevalence of pain in patients with cancer: a systematic review of the past 40 years
2007 Standout
Idarubicin
1991
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
2002
Clinical Pharmacology of 5-Fluorouracil
1989 Standout
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
2012 Standout
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study
2008 Standout
The dawning era of polymer therapeutics
2003 Standout
Adriamycin
1974 Standout
Iron Catalysis in Organic Synthesis
2015 Standout
Antineoplastic Drugs
1978
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment
2009 Standout
Carboplatin: the clinical spectrum to date
1985
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
2005 Standout
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
Eye toxicity of cancer chemotherapy: A review of the literature
1981
Oral Idarubicin in Solid Tumour Chemotherapy
1995
Management of brain metastases from breast cancer by combination chemotherapy
1983
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Anthracycline analogs The past, present, and future
1986
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
2014 Standout
Prognostic effect of weight loss prior tochemotherapy in cancer patients
1980 Standout
Practical Methodologies for the Synthesis of Indoles
2006 Standout
Synthesis of 11-amino-substituted-9-methoxy-5-methyl-6H-pyrido[4,3-b]-carbazoles
1991
Occurrence, Biogenesis, and Synthesis of Biologically Active Carbazole Alkaloids
2012 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
1979 Standout
Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases
1986 Standout
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
2003 Standout
Intraperitoneal therapy in the management of ovarian carcinoma.
1990
High-performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urine
1986
Role of Quinones in Toxicology
2000 Standout
Clinical trial of intra-arterial polychemotherapy in the treatment of carcinoma of the oral cavity
1978
Ferroptosis as a target for protection against cardiomyopathy
2019 Standout
The treatment of soft tissue sarcomas with focus on chemotherapy: A review
1986
A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
1987
Phase II study of 9-hydroxy-2N-methylellipticinium acetate
1984
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
2013 Standout
Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions
2016 Standout
A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma
1982
Intrapleural Chemotherapy Without Pleurodesis for Malignant Pleural Effusions
1994
The Anthracycline Antineoplastic Drugs
1981 Standout
Nephrotoxicity Induced by Cancer Chemotherapy With Special Emphasis on Cisplatin Toxicity
1986
Review : Synthetic Polymers with Intrinsic Anticancer Activity
1991
Isolation and Synthesis of Biologically Active Carbazole Alkaloids
2002 Standout
Cisplatin
1984 Standout
Works of Y. Kenis being referenced
EORTC protocol for therapy of metastatic soft tissue sarcomas, a randomized trial
1977
Action de la mitomycine C dans 65 cas de tumeurs malignes. Comparaison de l’effet de doses faibles, répétées et de doses ‘massives’
1964
Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days
1988
Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against human normal myeloid stem cells and human malignant cells In vitro
1987
Intraperitoneal Chemotherapy With Cisplatin and Melphalan
1988
Adjuvant immunotherapy by levamisole in resectable lung cancer: A control study
1980
Phase I clinical trial with carbetimer
1989
Prognostic value of the superior vena cava syndrome as the presenting sign of small cell anaplastic carcinoma of the lung
1980
Human pharmacokinetics of esorubicin (4′ -deoxydoxorubicin)
1985
E.O.R.T.C. protocol for the therapy of metastatic soft tissue sarcoma, a randomized trial
1977
EORTC Randomized Trial for the Adjuvant Therapy ofT1 Bladder Carcinomal
1976
Results of a clinical trial with intermittent doses of adriamycin in lung cancer
1972
Additive toxicity of vincristine and other drugs for the peripheral nervous system. Three case reports.
1971
Pharmacokinetics of adriamycin and adriamycin-DNA complex in L1210 mice and men
1977
Phase I study of oral idarubicin given with a weekly schedule
1986
Combination chemotherapy with CCNU, vincristine and methotrexate in primary and metastatic brain tumors
1975
Phase I study of carboplatin given on a five-day intravenous schedule.
1983
Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule
1982
Intermittent dose schedule of mitomycin C (NSC-26980) in solid tumors.
1972
Results of a E.O.R.T.C. randomized trial of cyclophosphamide and radiotherapy in inoperable lung cancer: Prognostic factors and treatment results
1978
Chemotherapy of advanced soft-tissue sarcomas in adults
1977